title: Laboratory investigation of platelet function in patients with thalassaemia.
abstract: The aim of this study was to investigate platelet function in patients with thalassaemia and to detect any relation to chelation treatment (deferasirox or deferiprone/deferiprone plus desferioxamine). Thirty-three transfusion-dependent patients with thalassaemia were included. The investigation consisted of aggregation testing of platelet-rich plasma by light transmission aggregometry (LTA) with the use of 5 agonists as well as the global test of haemostasis by means of the PFA-100 platelet function analyser. In 66.67% of the patients, there was reduced LTA to at least one agonist and in 18.18% there was reduced LTA to two or more agonists. The PFA-100 test was prolonged in 60.6% of the cases. An abnormal LTA and a prolonged PFA-100 time were recorded in 33.3% of the patients and 27.4% had a normal aggregation and PFA-100 test. No correlation between chelation regimen and either LTA or PFA-100 test was found. The abnormal LTA can be explained either by the release of ADP from the haemolysed red blood cells, which leads to defective platelet aggregation, or by the presence of two platelet populations. An in vitro effect without an in vivo impact could be an alternative explanation. In patients with thalassaemia, the reduced LTA and the prolonged PFA-100 closure time could be an in vitro effect and has a close correlation to the bleeding phenotype of each patient.
authors.affiliation: Thalassaemia Unit, Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece.
authors.forename: S
authors.initials: S
authors.lastname: Theodoridou
authors.forename: M
authors.initials: M
authors.lastname: Economou
authors.forename: T-A
authors.initials: TA
authors.lastname: Vyzantiadis
authors.forename: A
authors.initials: A
authors.lastname: Teli
authors.forename: E
authors.initials: E
authors.lastname: Vlachaki
authors.forename: N
authors.initials: N
authors.lastname: Neokleous
authors.forename: A
authors.initials: A
authors.lastname: Kargioti
authors.forename: S
authors.initials: S
authors.lastname: Vakalopoulou
authors.forename: V
authors.initials: V
authors.lastname: Garypidou
authors.forename: N
authors.initials: N
authors.lastname: Gombakis
authors.forename: F
authors.initials: F
authors.lastname: Papachristou
mesh_terms: D000293:Adolescent; D000328:Adult; D001565:Benzoates / Q000627:therapeutic use; D001792:Blood Platelets / Q000502:physiology*; D002648:Child; D000077588:Deferasirox; D000077543:Deferiprone; D003676:Deferoxamine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation; D010979:Platelet Function Tests; D011728:Pyridones / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use; D055815:Young Adult; D017086:beta-Thalassemia / Q000097:blood* / Q000188:drug therapy
chemical_list: D001565:Benzoates; D007502:Iron Chelating Agents; D011728:Pyridones; D014230:Triazoles; D000077543:Deferiprone; D003676:Deferoxamine; D000077588:Deferasirox